SciELO - Scientific Electronic Library Online

 
vol.30 issue1Evaluation of the appropriateness of stays in a third level hospitalHealth Related Quality of life in patients with diabetes mellitus type 2 author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Anales del Sistema Sanitario de Navarra

Print version ISSN 1137-6627

Abstract

ARROYO, M.P.  and  JIMBERT, J.. Anticoagulation in atrial fibrillation and antiplatelet in diabetes mellitus type 2: How do we do it. Anales Sis San Navarra [online]. 2007, vol.30, n.1, pp.37-44. ISSN 1137-6627.

Background: In spite of evidence about the interest of anticoagulation in Atrial Fibrillation (AF) and antiplatelet to diabetics (DM) type 2, the national and international references describe a low level of assumption of those criteria in practice. Published studies on these aspects are unavailable in Navarre. Methods: Cross-sectional study. Population: primary care patients (1,600 people 15 years). Inclusion criteria: patients diagnosed of AF / with diagnosis of DM type 2, over 40. Variables: age and sex, criteria of AF with high embolic risk (6% annual) and cardiovascular risk factors in DM2. Data collection: in computerised registers of Organisation and Management Information. Analysis: (population universe studied), results in absolute numbers and percentages. Results: Twenty-five people with diagnosis of chronic FA (14 women and 11 men, average age 78.36 years); 22 (81.8%) show high embolic risk. There were counter-indications in 4 cases. Type 2 diabetics totalled 69 people (29 women and 40 men, average age 68.57 years). There are 16 (23.1%) in primary prevention (PP), 26 (37.3%) in secondary prevention (SP), and 27 (39.1%) do not follow antiplatelet therapy. There is counter-indication in 8 cases and 14 patients (20.2%) would be susceptible to intervention. Conclusions: - The results of oral anticoagulant therapy (OAT) in high risk AF exceed the reviewed references. - The PP with DM2 are similar figures to other studies; a area of improvement was detected. - We must ask for the opinion of the patient and individualise these therapies. - The family doctor has a significant responsibility in cardiovascular prevention of the patients affected by these problems.

Keywords : Anticoagulation; Auricular fibrillation; Antiplatelet; Primary prevention; Diabetes mellitus.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License